Interferon alpha (IFN alpha) induces cytogenetic responses in patients with chronic myeloid leukemia (CML) who relapse after allogeneic bone marrow transplantation (BMT). The purpose of this study was to analyze the therapeutic role of IFN alpha in this setting. The experience of a single institution and the published results on this topic were evaluated. We have included patients who received IFN alpha as a single agent, excluding those patients who received previous or simultaneous donor leukocyte infusions. The outcomes of 11 patients treated in our center and those of 108 previously reported patients have been analyzed. Five out of 11 patients treated in our institution obtained a complete cytogenetic response (CGR). Two patients continue in complete cytogenetic response 3.5 and 8.2 years later, and the qualitative RT-PCR is negative for bcrabl RNA. The CGR has been transient in one patient, and follow-up is short in the other two. Secondary effects have been acceptable, with myelosuppression as the main toxic effect. Graft-versus-host disease did not occur. The literature review identified 108 patients treated with IFN alpha as sole therapy for relapsed CML. Cytogenetic response and CGR seem to be better in patients with cytogenetic relapse, as compared to patients with hematologic relapse (61% vs 45% and 45% vs 28%, respectively). Several patients remained in CGR for more than 5 years. This overview also suggests that CGR is more frequent when IFN alpha is used in patients relapsing after non T-depleted BMT. IFN alpha induces complete cytogenetic response in nearly half of the patients with CML who relapse after allogeneic BMT, with acceptable toxicity. We believe that these results using IFN alpha as a front-line therapy for CML relapsing after BMT warrant a randomized comparison with donor lymphocyte infusions. Keywords: interferon alpha; chronic myeloid leukemia; allogeneic bone marrow transplantation; relapse The EBMT has estimated a 54% actuarial probability of survival at 8 years for CML patients receiving an unmanipulated allogeneic BMT in first chronic phase. Although the probability of relapse at 8 years is 19%, late relapses may be more frequent than previously assumed.
The EBMT has estimated a 54% actuarial probability of survival at 8 years for CML patients receiving an unmanipulated allogeneic BMT in first chronic phase. Although the probability of relapse at 8 years is 19%, late relapses may be more frequent than previously assumed. 1 In patients receiving unmanipulated bone marrow, many cytogenetic relapses appear to be transient, 2 although the reappearance of the Ph 1 chromosome beyond the first 6 months post transplantation heralds hematologic relapse in the majority of patients. 3 This situation is more frequent in T-depleted grafts. 4 In patients relapsing after BMT, IFN alpha can induce complete hematologic and cytogenetic responses in onethird of hematologic relapses. 5 Recently, Higano et al 6 communicated that complete cytogenetic response was obtained in 12 out of 14 patients treated for cytogenetic relapse.
Since 1988, our group has offered IFN alpha as initial therapy for CML patients who relapse after BMT. Part of this experience has been previously communicated. 7 This paper describes the results obtained in a group of 11 consecutive patients who relapsed after allogeneic BMT, and reviews the results in 108 patients treated with IFN alpha as single therapy in this setting.
Patients and methods

Patient characteristics
Eleven patients who relapsed after allogeneic BMT have been included. They were entered consecutively. Patient status pre-BMT and characteristics of the BMT procedure and relapse are given in Table 1 . All were recipients of HLA-identical, sibling, unmanipulated bone marrow. Nine patients received cyclosporine and short methotrexate; one patient received cyclosporine and prednisone (IDN 22) and one patient received only cyclosporine as GVHD prophylaxis (IDN 902).
In the post-BMT period, cytogenetic studies were performed every 6 months in the first 2 years, and annually thereafter. Relapse was defined as the presence of the Ph 1 chromosome on bone marrow cytogenetic studies after BMT, if this was detected at least 6 months after BMT. If the presence of the Ph 1 chromosome was detected earlier, the working definition of cytogenetic relapse included the presence of more than 15% Ph 1 -positive metaphases and per- 
Treatment regimen and follow-up
Hematologic relapse was treated initially with hydroxyurea until a leukocyte count of 10 000/l was obtained. Thereafter, hydroxyurea was stopped and all patients received IFN alpha as sole therapy. The target dose was 5 MU/m 2 /day s.c. Dose adjustments were made according to WHO toxicity. Hematologic and cytogenetic response were classified according to Talpaz et al. 8 Date of analysis was 1 March 1998.
Laboratory investigations
Cytogenetic studies were performed 3 and 6 months after IFN, and 6 monthly thereafter. The karyotype analysis was carried out on bone marrow cells by direct and culture methods, without stimulation. 9 MBCR rearrangement was studied by qualitative Southern, as previously described. 10 Chimerism studies were performed using PCR amplification of VNTR regions, as previously published.
11
Detection of minimal residual disease was accomplished by nested RT-PCR in RNA extracted from total nucleated cells from bone marrow and/or peripheral blood samples, as previously described. 12 
Sensitivity of PCR detection of the chimeric transcript
Sensitivity assays were performed by dilution of K562 cells in cells obtained from a pool of normal blood donors. Sensitivity was estimated by direct visualization of bands stained with ethidium bromide. Analytical sensitivity was 1/10 5 cells.
Results
Results are given in Table 1 . IFN alpha 2a treatment was initiated at a median of 3 months after relapse (range 0-18).
Median maintenance dose of IFN was 4.3 MU/day (2.2-9).
Hematologic response
Three out of eight patients with hematologic relapse obtained complete hematologic response (CHR) and three partial hematologic response (PHR). The three patients who relapsed with isolated cytogenetic relapse remained in hematologic remission during treatment.
Cytogenetic response
Five patients obtained complete cytogenetic response (patients IDN 42, 22, 8, 902 and 903). This response was durable in two patients (patients IDN 8 and 22), and has continued so for 3.5 and 8.2 years, respectively. It was transient in one (patient IDN 42). The response has had a short follow-up in two patients (patients IDN 902 and 903). The median time for obtaining a cytogenetic response was 7 months (6-15).
The evolution of patient 22 warrants a brief comment. She experienced a late relapse (44 months after BMT), with clonal evolution and cytogenetic criteria of accelerated phase (double Ph 1 ). IFN alpha 2a was started 18 months later and resulted in a CHR in 21 days and a complete cytogenetic response (CGR) after 15 months. At present, 9.5 years after IFN, she has a durable CGR, with a Karnofsky score of 100%, and receives 4.5 MU of IFN alpha every other day. This CGR has lasted 8.5 years. This patient has, to our knowledge, the longest CGR after IFN alpha in this context.
Molecular studies
The temporal profile of molecular analysis of the patients who achieved CGR is shown in Figure 1 . In patients with CGR, simultaneous molecular analysis disclosed complete donor chimerism on PCR analysis of VNTR regions in three patients; in patient IDN 903, 5% of mononuclear cells and 3% of granulocytes in the bone marrow were of recipient origin. MBCR rearrangement analysis was used in patient IDN 22, when cytogenetic analysis was not evaluable due to lack of metaphases. This occurred in four out of 17 evaluations, and MBCR rearrangement was detected in one of them. The rearrangement disappeared after the IFN dose was increased.
Since 1993, RT-PCR analysis has been performed in all the patients who obtained CGR. Disappearance of bcr-abl RNA resulted in two patients who achieved CGR (IDN 8  and 22 ). As Figure 1 shows, the molecular response has fluctuated in patient IDN 22. Patient IDN 8 showed PCR negativity in peripheral blood 6 months after CGR was reached, but bcr-abl RNA was present in bone marrow until the last evaluation, 37 months after CGR was reached.
Toxicity
We have not observed induction or worsening of GVHD in our patients. The more frequent secondary effects have been flu-like syndrome, alopecia and myelosuppression. In three patients the dose had to be decreased due to toxicity: anemia (patient IDN 43), neutropenia (patient IDN 903) and weight loss Ͼ15% (patient IDN 42). 
Course of patients treated with IFN alpha and who received donor lymphocyte infusions
Patient IDN 43: After IFN alpha failed to attain CHR or cytogenetic response, he received a second BMT from the same donor. His bone marrow then disclosed the presence of a cytogenetic clonal evolution (in addition to Ph 1 chromosome and 14q+, 9q− and 17q− were detected). The patient did not develop GVHD. Cytogenetic relapse was detected 9 months after the second BMT, with 14% Ph 1 -positive metaphases, and the same clonal abnormalities. He received donor leukocyte infusions (DLI), at a total dose of 8.4 ×10 7 T lymphocytes/kg, plus low-dose IFN alpha. Complete cytogenetic response was seen at 2 months, which persists. Extensive chronic GVHD developed, and he is currently alive, 2.3 years after DLI. He is receiving immunosuppressive therapy, with a Karnofsky status of 70%.
Patient IDN 900:
This patient has received one course of DLI plus low-dose IFN alpha, with a total dose of 7.7 × 10 7 T lymphocytes/kg. He remains in PHR, and no signs of GVHD have developed 4 months after start of DLI.
Patient IDN 901:
In this patient, the percentage of Ph 1 metaphases increased during the first 6 months of IFN alpha treatment (from 64% to 100%). She received two courses of DLI plus low-dose IFN alpha, the first with 1.1 × 10 8 T lymphocytes/kg, and 2 months later a second DLI with 3.1 × 10 8 T lymphocytes/kg. One month after the last DLI she developed grade IV acute GVHD, without cytopenia. Bone marrow analysis then showed a normocellular mar-row, with 100% XY, Ph 1 -negative metaphases (50/50). The patient died 2 months later, 1 year after relapse.
Survival
Seven patients are alive, a median of 53 months after IFN (range 3-114 months). Four patients have died; patient IDN 1 due to hepatic cirrhosis, patients IDN 6 and 24 with transformation, and patient 901 because of acute GVHD after DLI.
Discussion
Interferon alpha treatment has induced complete cytogenetic responses in a substantial number of CML patients who relapsed after BMT. 5 Activity of IFN in the BMT setting can combine antiproliferative and immunomodulating effects. 13 A possible enhancing effect of IFN on GVHD and/or the graft-versus-leukemia effect appears physiologically sound; 14, 15 therefore, the efficacy of IFN alpha after allogeneic BMT might be more than that observed in the pre-BMT setting.
Our study confirms that IFN alpha can induce durable cytogenetic responses in CML patients who relapse after BMT. Five out of 11 patients have had a complete cytogenetic response. This response reverted to partial in one patient. Although in two patients the follow-up is short, it is important to point out that in the other two patients the complete cytogenetic response has been maintained over a long period: 42 and 99 months, respectively. This durable CGR, maintained with low-dose IFN, may explain the disappearance of the abnormal RNA when using a moderately sensitive RT-PCR (10 −5 cells). It is quite possible that a more sensitive RT-PCR assay would be able to detect the presence of the abnormal transcript. IFN alpha can induce complete molecular responses in patients with durable complete cytogenetic responses (CGR). This has been described by Talpaz et al 16 in first chronic phase patients. Pigneux et al 17 have described the same phenomenon in patients relapsing after BMT and treated with IFN. The clinical significance of this molecular response is at present unknown. From the physiological point of view, it is important to stress that bcr-abl-positive hematopoietic progenitors have been demonstrated in patients with complete molecular response after IFN. 16 Our results are consistent with the picture that emerges after reviewing the published data on this topic. To date, we are aware of 108 patients who have received IFN alpha as treatment for CML relapse after BMT. 5, 6, [17] [18] [19] [20] [21] [22] Forty-four patients with isolated cytogenetic relapse have been reported (Table 2) . Response has been documented in 27 of them (61%), complete in 20 (45%). The time to CGR has been between 2 and 17 months. Duration of CGR has been quite prolonged, and several patients have remained in CGR more than 5 years. Results have been slightly poorer in patients with hematologic relapse (Table 3) . Out of 64 patients treated with this disease status, cytogenetic response has resulted in 45%, and CGR in 18 (28%). Response usually occurred in the first year of treatment, but later CGRs have been described. 
T-dep = T cell-depleted; Non T-dep = non-T cell-depleted; MU = megaunits; CGR = complete cytogenetic response; NS = not stated. 
T-dep = T cell-depleted; Non T-dep = non-T cell-depleted; MU = megaunits; CGR = complete cytogenetic response; NS = not stated.
Major secondary effects were infrequent in these series. GVHD was described in one patient after treatment with IFN alpha, but the short duration of the treatment (6 days) makes the role of IFN alpha difficult to determine. 23 Hypoplasia has been described in one patient. 24 IFN toxicity appears to be less than toxicity associated with other treatments for relapsed CML. Donor lymphocyte infusions (DLI) are very effective in these patients. Kolb et al 25 have reviewed the EBMT experience in 70 CML patients. CGR can be obtained in 80% of the patients who relapse in chronic phase. However, GVHD and myelosuppression cause major problems with this therapy, with half of the patients developing GVHD.
Response to IFN alpha appeared to be influenced by the status of T-depletion of the graft. Complete cytogenetic response has been more frequently seen in patients with non-T-depleted BMT, and this difference is apparent in cytogenetic relapse (14/17 vs 2/17) as well as in hematologic relapse (9/25 vs 2/16) ( Tables 2 and 3) . Although an analysis of the Sociéte Française de Greffe de Moelle has not detected an influence of type of GVHD prophylaxis on cytogenetic response to IFN, 17 the rate of CGR was slightly higher in non-T-depleted grafts (7/16 vs 4/17) (J Reiffers, personal communication). This fact must be taken into account when analyzing the results of retrospective studies focused on the role of IFN after BMT. An EBMT survey has found that among patients with cytogenetic relapse, partial or complete disappearance of Ph-positive cells occurred in 40% of untreated patients and in 42% of those treated with interferon (IFN). However, the IFN group contained significantly more patients with T-depleted grafts (22 out of 24). 26 It is of interest that depletion of T cells from the previous marrow graft had a weak 25 or no influence 27 on the response of relapsed CML to DLI. Although an European collaborative study has found that GVHD and myelosuppression were more frequently induced by DLI in patients with Tdepleted grafts, 25 other authors have not detected this effect. 27 Studies are needed to ascertain if there is any relationship between the occurrence of GVHD after BMT and response to IFN. It must be said that conflicting results have been shown in patients receiving DLI: some authors have reported that absence of GVHD is associated with response, 25 whereas others have noted that previous chronic GVHD favorably influences the response to DLI. 27 The degree of cytogenetic response to IFN positively influences survival in first chronic phase. 28, 29 This is also true for patients who relapse after BMT. Pigneux et al 17 have shown that the probability of survival was statistically higher for patients who achieve CGR than for those with incomplete GR.
In conclusion, IFN alpha seems to be an effective therapy in CML patients relapsing after BMT. Forty percent of CGR can be expected in patients with cytogenetic relapse, and toxicity does not appear to be a major problem. Taking into account these results, we feel it would be reasonable to concentrate on schemes for early detection of relapse. Qualitative or quantitative PCR seem to be valuable in predicting cytogenetic relapse, thus indicating patients more prone to cytogenetic relapse. [30] [31] [32] Cytogenetic relapse can be first treated with IFN alpha. Patients who gain no cytogenetic response to IFN may be suitable candidates for donor lymphocyte infusion. We feel that this approach should be prospectively compared with DLI as a first option after cytogenetic relapse.
IFN alpha may be less effective in patients relapsing after a T-depleted BMT. This point warrants further study; if confirmed, it may merely reflect the increased tendency to relapse in the setting of T depletion. Alternatively, it may be that IFN alpha after BMT acts not only as a myelosuppressive agent, but also as an enhancer of the GVL effect.
